Taysha Gene Therapies Inc
NASDAQ:TSHA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/OCF
Price to Operating Cash Flow (P/OCF) ratio compares a company`s market value to the cash it generates from its core operations.
Price to Operating Cash Flow (P/OCF) ratio compares a company`s market value to the cash it generates from its core operations.
Valuation Scenarios
If P/OCF returns to its Industry Average (16.6), the stock would be worth $-5.44 (185% downside from current price).
| Scenario | P/OCF Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | -19.6 | $6.4 |
0%
|
| Industry Average | 16.6 | $-5.44 |
-185%
|
| Country Average | 13.3 | $-4.36 |
-168%
|
Forward P/OCF
Today’s price vs future operating cash flow
Peer Comparison
| Market Cap | P/OCF | P/E | ||||
|---|---|---|---|---|---|---|
| US |
|
Taysha Gene Therapies Inc
NASDAQ:TSHA
|
1.8B USD | -19.6 | -16.7 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | -211 714.7 | -160 127.7 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
355.3B USD | 18.7 | 84.9 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
186.5B USD | 18.9 | 24.3 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
164.9B USD | 16.6 | 19.5 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
111.2B USD | 30.4 | 28 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | -531.3 | -533.6 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
78.9B USD | 16.3 | 18 | |
| NL |
|
argenx SE
XBRU:ARGX
|
42.4B EUR | 122.8 | 38.4 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | -85.8 | -61.8 | |
| AU |
|
CSL Ltd
ASX:CSL
|
62.3B AUD | 11.8 | 30.5 |
Market Distribution
| Min | 0 |
| 30th Percentile | 8.8 |
| Median | 13.3 |
| 70th Percentile | 20.1 |
| Max | 3 188 432.5 |
Other Multiples
Taysha Gene Therapies Inc
Glance View
Taysha Gene Therapies, Inc.is a patient-centric, clinical-stage gene therapy company, which engages in the development and commercialization of adeno-associated viruses (AAV) based gene therapies for the treatment of monogenic diseases of the central nervous system. The company is headquartered in Dallas, Texas and currently employs 178 full-time employees. The company went IPO on 2020-09-24. The firm is focused on developing and commercializing adeno-associated virus (AAV)-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS). Its portfolio of gene therapy candidates targets a range of neurological indications across three distinct therapeutic categories: neurodegenerative diseases, neurodevelopmental disorders and genetic epilepsies. Its product candidates include TSHA-101, which is being developed for the treatment of giant axonal neuropathy (GAN); TSHA-102, a neurodevelopmental disorder product candidate, which is being developed for the treatment of Rett syndrome; TSHA-118, which is a AAV9 viral vector that expresses human codon-optimized Ceroid Lipofuscinosis Neuronal 1 complementary deoxyribonucleic acid under control of the chicken b-actin hybrid promoter, and TSHA-105, a gene replacement therapy for the treatment of SLC13A5 deficiency.
